← Back to headlines
Agios Plans Q2 sNDA Filing for Mitapivat in Sickle Cell Disease
Agios Pharmaceuticals intends to file a supplemental New Drug Application (sNDA) for mitapivat in sickle cell disease during Q2, projecting a market opportunity exceeding $10 billion by 2030.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
